News | June 05, 2021
Jubilant Pharmova posts Q4FY21 consolidated PAT of Rs. 213.90 Cr
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Subscribe To Our Newsletter & Stay Updated
